Group 1 - The company has decided to abolish the supervisory board, transferring its responsibilities to the audit committee of the board of directors, and will amend the relevant provisions in the Articles of Association accordingly [1][2] - The proposal to abolish the supervisory board and amend the Articles of Association has been approved by the supervisory board and will be submitted for shareholder meeting approval [2] - The proposal to abolish the "Rules of Procedure for the Supervisory Board of Beijing Northland Biotechnology Co., Ltd." has also been approved, as the supervisory board will no longer exist [2] Group 2 - The meeting was convened in accordance with the Company Law and the Articles of Association, with all voting results being legal and valid [1] - All three supervisors were present or authorized to attend the meeting, with one supervisor participating via telecommunication due to work commitments [1] - The proposals do not involve related party transactions and do not require abstention from voting [2]

证券代码：430047 证券简称：诺思兰德 公告编号：2025-066 北京诺思兰德生物技术股份有限公司独立董事工作制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第六届董事会第二十二次会议，审议通过了《关于制定及修订公司部分内 部管理制度的议案（尚需股东会审议）》之子议案 2.07： 《修订〈独立董事工作制 度〉》，表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 北京诺思兰德生物技术股份有限公司 第一章 总则 第一条 为进一步完善北京诺思兰德生物技术股份有限公司（以下简称"公 司"）治理结构，充分发挥公司独立董事作用，促进公司规范运作，根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、《北京证券交易所上市公司持续监管办法（试行）》《上市公 司独立董事管理办法》、 ...

证券代码：430047 证券简称：诺思兰德 公告编号：2025-064 北京诺思兰德生物技术股份有限公司利润分配管理制度 度〉》，表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 北京诺思兰德生物技术股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第六届董事会第二十二次会议，审议通过了《关于制定及修订公司部分内 部管理制度的议案（尚需股东会审议）》之子议案 2.05： 《修订〈利润分配管理制 第一章 总则 第一条 为进一步规范北京诺思兰德生物技术股份有限公司（以下简称"公 司"）的利润分配行为，建立科学、持续、稳定的分配机制，增强利润分配的透 明度，保证公司长远可持续发展，保护中小投资者合法权益，根据《中华人民共 和国公司法》 （以下简称"《公司法》"）、 《中华人民共和国证券法》、 《北京证券交 易所股票上市规则》、 ...

Group 1 - The core point of the article is the establishment and operational framework of Beijing Northland Biotechnology Co., Ltd., including its legal foundation, organizational structure, and governance principles [1][2][3][4]. - The company was established as a joint-stock company based on the transformation of Beijing Northland Biotechnology Co., Ltd. and is registered in Haidian District, Beijing [2][3]. - The registered capital of the company is RMB 274.271974 million [3]. Group 2 - The company's business purpose is to operate legally, combining production and capital operations, focusing on the development of new drug projects, and expanding related industries to achieve multi-faceted development [5]. - The company’s business scope includes technology development, transfer, and consulting, investment and asset management, sales of biological products, and various forms of drug retail and wholesale [5]. Group 3 - The company has issued a total of 274,271,974 shares, all of which are RMB ordinary shares [6][7]. - The company can increase its capital through various methods, including issuing shares to unspecified objects or existing shareholders [7][8]. - The company is prohibited from repurchasing its own shares except under specific circumstances, such as reducing registered capital or merging with another company [8][9]. Group 4 - The company’s shares must be transferred in accordance with the law, and the company does not accept its shares as collateral [9][10]. - Major shareholders and executives are restricted from selling their shares within two full accounting years if the company has not yet made a profit [10][11]. Group 5 - The company’s shareholders have rights to dividends, voting, and other benefits proportional to their shareholdings [11][12]. - The company must hold annual and temporary shareholder meetings, with specific procedures for calling and conducting these meetings [12][13][14].

证券代码：430047 证券简称：诺思兰德 公告编号：2025-061 北京诺思兰德生物技术股份有限公司股东会议事规则 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第六届董事会第二十二次会议，审议通过了《关于制定及修订公司部分内 部管理制度的议案（尚需股东会审议）》之子议案 2.02： 《修订〈股东会议事规则〉》， 表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 北京诺思兰德生物技术股份有限公司 第一章 总 则 则。 第一条 为规范北京诺思兰德生物技术股份有限公司（以下简称"公司"）行 为，保证股东会依法行使职权，根据《中华人民共和国公司法》 （以下简称"《公 司法》"）、 《中华人民共和国证券法》 （以下简称"《证券法》"）、 《上市公司股东会 规则》、 《北京证券交易所股票上市规则》 （以下简称"《股票上市规则》"）、 《 ...

Core Points - The company has established a set of rules for online voting at shareholder meetings to protect investors' rights and ensure compliance with relevant laws and regulations [1][2][5] - The online voting system is provided by China Securities Depository and Clearing Corporation Limited, allowing shareholders to exercise their voting rights through internet technology [2][3] - The board of directors approved the proposal for the online voting implementation rules, which will be submitted for shareholder meeting approval [1][6] Chapter Summaries Chapter 1: General Provisions - The rules aim to standardize online voting behavior at shareholder meetings and protect investors' legal rights [1] - The rules are based on the Company Law and relevant regulations [1] Chapter 2: Preparation for Online Voting - The company must provide clear information about the voting code, voting abbreviation, voting time, and agenda in the shareholder meeting notice [2] - There should be at least a 2 trading day gap between the record date and the start of online voting [2] Chapter 3: Voting and Counting Rules - Shareholders can vote through the online system, and multiple votes on the same proposal will be counted as attendance [3][4] - Votes exceeding the number of shares owned will be considered abstentions [3] - The first valid vote will be considered in cases of multiple voting methods [4][5] Chapter 4: Miscellaneous - The rules will take effect after being approved by the shareholder meeting [6] - The board of directors is responsible for interpreting the rules [6]

Core Viewpoint - Beijing Northland Biotechnology Co., Ltd. has revised its related party transaction management system to ensure fairness, transparency, and protection of the rights of non-related shareholders, in compliance with relevant laws and regulations [1][2]. Section Summaries Chapter 1: General Principles - The purpose of the revised system is to ensure that related party transactions are conducted fairly and do not harm the interests of the company and non-related shareholders [2]. Chapter 2: Related Parties and Relationships - Related parties include both legal entities and natural persons that have significant control or influence over the company [3][4]. - The criteria for identifying related parties include ownership stakes, control relationships, and significant influence in financial and operational decisions [4][5]. Chapter 3: Related Transactions - Related transactions encompass various activities such as asset purchases, investments, guarantees, financial assistance, and management contracts [8][9]. - Transactions must adhere to principles of honesty, equality, and fairness, ensuring that they do not harm the interests of the company or its non-related shareholders [9][10]. Chapter 4: Decision-Making Authority and Review Procedures - Transactions exceeding 2% of the company's total audited assets or 30 million yuan require shareholder meeting approval, along with an assessment report [7]. - The board of directors must review transactions that meet specific thresholds, ensuring independent directors are involved in the decision-making process [7][8]. Chapter 5: Miscellaneous Provisions - The management system will take effect upon approval by the shareholders' meeting, and the board of directors is responsible for its interpretation [18].

Core Viewpoint - Beijing Northland Biotechnology Co., Ltd. has revised its Commitment Management System to enhance the regulation of commitments made by controlling shareholders, actual controllers, related parties, and other committers, ensuring the protection of minority investors' rights [1][2]. Chapter Summaries Chapter 1: General Principles - The revised system aims to strengthen the regulation of commitments made by the company and its related parties, in accordance with relevant laws and regulations [2]. Chapter 2: Commitment Management - Committers must provide clear performance deadlines for commitments related to stock issuance, refinancing, mergers, and other governance activities, ensuring compliance with industry policies [2][3]. - Committers are required to analyze the feasibility of commitments before making them and disclose any necessary approvals from regulatory authorities [2]. - Commitments must be specific, clear, and actionable, and the company is responsible for timely disclosure of these commitments [2][3]. Chapter 3: Rights and Obligations of Committers - Committers must adhere to their commitments and cannot change or waive them without valid reasons [4]. - Committers can change or waive commitments only under specific circumstances, such as changes in laws or natural disasters [4][5]. - The company must disclose reasons for any changes or waivers of commitments and seek shareholder approval for such changes [5]. Chapter 4: Supplementary Provisions - The system will be implemented after approval by the company's shareholders and will be interpreted by the board of directors [6].

Core Points - The company held its 22nd meeting of the 6th Board of Directors on September 1, 2025, where it approved the proposal to revise the "Rules of Procedure for Board Meetings," which will be submitted for shareholder approval [1][2]. Summary by Sections Chapter 1: General Provisions - The rules aim to standardize the board's decision-making processes and enhance operational efficiency in accordance with relevant laws and regulations [1]. - The board consists of 9 directors, including 3 independent directors and 6 non-independent directors, with one chairman [2]. Chapter 2: Convening the Board - The board must hold at least 2 regular meetings annually, with the chairman responsible for convening and notifying directors at least 10 days in advance [2][3]. - Directors can propose temporary meetings under specific conditions, such as requests from shareholders or a third of the directors [3]. Chapter 3: Conducting Board Meetings - Meetings must follow established procedures, with adequate notice and materials provided to all directors [3][4]. - A quorum requires more than half of the directors to be present, and the chairman leads the meeting [5][6]. Chapter 4: Voting and Decision-Making - Voting is conducted by a show of hands, written ballot, or electronic means, with each director having one vote [9][10]. - Decisions require a majority of votes from present directors, and related-party transactions must be abstained from by interested directors [10][11]. Chapter 5: Documentation and Record-Keeping - The board secretary is responsible for maintaining accurate records of meetings, including attendance, agenda, and voting results [12][13]. - Meeting records must be preserved for at least 10 years, and confidentiality regarding sensitive decisions is mandated [13][14].

证券代码：430047 证券简称：诺思兰德 公告编号：2025-067 北京诺思兰德生物技术股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第六届董事会第二十二次会议，审议通过了《关于制定及修订公司部分内 部管理制度的议案（尚需股东会审议）》之子议案 2.08： 《修订〈独立董事专门会 议工作制度〉》，表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 北京诺思兰德生物技术股份有限公司 第一章 总则 第一条 为完善、规范和保障北京诺思兰德生物技术股份有限公司（以下简 称"公司"）独立董事的权利和义务，充分发挥独立董事作用，根据《中华人民 共和国公司法》、《中华人民共和国证券法》、《上市公司独立董事管理办法》《北 京证券交易所股票上市规则》（以下简称"《上市规则》"）《北京证券交易所上市 公司持续监管指引第 1 号—独立董 ...